PCV 2 vaccine gets US approval
Animal medicine manufacturer Boehringer Ingelheim Vetmedica (BIVI) has
received approval from the US animal and plant health inspection service for a
new vaccine called IngelvacÂ® CircoFlexâ„¢.
The vaccine is to be used against pig diseases caused by Porcine Circovirus
type 2 (PCV2).
According to Klaas Okkinga, marketing manager for BIVI, the vaccine is a
single-dose, 1 ml vaccine that provides the highest level of efficacy and safety
"It's highly effective in immunising pigs as young as three weeks of age
prior to exposure to PCV2, and provides long-lasting protection without the
systemic irritation and tissue reactions some vaccines can cause."
In addition, the vaccine has a short 21-day withdrawal period and positive
pork quality assurance benefits that are important to producers, Okkinga adds.
"It has been thoroughly field tested and we are confident this vaccine will help
producers more effectively prevent porcine circovirus associated disease."
One of the most well-known diseases associated with PCV 2 is Post-weaning
Multisystemic Wasting Syndrome (PMWS
The vaccine will be widely available to producers in the first quarter of
To comment, register here
Or register to be able to comment.